Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03235869
Title Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

cutaneous T cell lymphoma

Therapies

Durvalumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.